[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].

Yizhuo Zhao, Yurong Chen, Hao Ji, Tianqing Chu, Baohui Han, Meilin LiaoPubMed 2004 · DOI

Abstract

Although the response rate tends to be higher in three-drug than in two-drug combined chemotherapy, but no significant difference is observed. Three-drug combinations often result in more toxicities. Two-drug combination GP may be the standard protocol for chemotherapy of advanced NSCLC. Three-drug combination NIP should be given to young patients with good performance status.
BibTeX
@inproceedings{zhao2004comparative,
  author = {Yizhuo Zhao and Yurong Chen and Hao Ji and Tianqing Chu and Baohui Han and Meilin Liao},
  title = {{[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].}},
  booktitle = {PubMed},
  year = {2004},
  doi = {10.3779/j.issn.1009-3419.2004.05.18},
}

Loading related content...

Figure